RadNet, Inc. (RDNT) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Generation ⢠Interest Pressure ⢠Thin Margins RDNT has adequate liquidity and strong cash generation, but thin margins, weak returns, and leverage/interest pressure make the investment case risky despite reasonable operating cash flow.
Price Behavior
Key Price Behavior Insights: ⢠Holding support ⢠Failed breakout ⢠Fading momentum Support Level: $54.6â$55.0 Resistance Level: $60.4â$60.7 RDNT weakened over the last month in a choppy downtrend, with support around $54.6â$55.0 holding so far but resistance near $60.4â$60.7 capping the rebound.
Sentiment & News
Key News Insights: ⢠Institutional Buying ⢠AI Collaboration ⢠Price Volatility RadNet's stock was volatile in mid-April as shares dipped on no new company catalyst, while new institutional buying and GE HealthCare's expanded DeepHealth AI screening collaboration highlighted growing strategic and investor interest.
AI Summary
RDNT should now be viewed as a leveraged hybrid imaging-plus-AI health platform with upside if DeepHealth/Gleamer/GE HealthCare translate into recurring revenue and margin expansion, but the key investment risk is that thin earnings and interest expense already exceeding EBIT leave little room for integration or reimbursement setbacks.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |